The global endoscopic retrograde cholangiopancreatography market size reached US$ 1.6 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 2.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.99% during 2023-2032.
Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging technique that diagnoses and treats abnormalities in the liver, gallbladder, bile ducts, and pancreas. It combines X-rays and a long, flexible, lightweight endoscope tube that passes through the esophagus, mouth, and stomach. It helps detect blockages, stones, infections, and tumors in the bile duct and fluid leakage from the pancreatic duct. Besides this, it is a less invasive procedure than open surgery and provides more detailed and accurate information about the pancreaticobiliary system. As a result, the demand for endotherapy devices is increasing across the globe to investigate dysphagia, diarrhea, weight loss, heartburn, and stool blood.
Furthermore, rising investments by governments and healthcare organizations of various countries in advanced endoscopy devices and improve endoscopy research is strengthening the market growth. Apart from this, the shifting consumer preference toward minimally invasive surgeries for a speedy recovery and minimal pain and rising awareness about ERCP devices like sphincterotomes are offering a favorable market outlook. Moreover, continuous improvements in healthcare infrastructure and a considerable rise in medical tourism are expected to propel market growth.
2. What is the expected growth rate of the global endoscopic retrograde cholangiopancreatography market during 2024-2032?
3. What are the key factors driving the global endoscopic retrograde cholangiopancreatography market?
4. What has been the impact of COVID-19 on the global endoscopic retrograde cholangiopancreatography market?
5. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the product?
6. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the procedure?
7. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the end user?
8. What are the key regions in the global endoscopic retrograde cholangiopancreatography market?
9. Who are the key players/companies in the global endoscopic retrograde cholangiopancreatography market?
Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging technique that diagnoses and treats abnormalities in the liver, gallbladder, bile ducts, and pancreas. It combines X-rays and a long, flexible, lightweight endoscope tube that passes through the esophagus, mouth, and stomach. It helps detect blockages, stones, infections, and tumors in the bile duct and fluid leakage from the pancreatic duct. Besides this, it is a less invasive procedure than open surgery and provides more detailed and accurate information about the pancreaticobiliary system. As a result, the demand for endotherapy devices is increasing across the globe to investigate dysphagia, diarrhea, weight loss, heartburn, and stool blood.
Endoscopic Retrograde Cholangiopancreatography Market Trends:
The growing global population and the rising prevalence of various chronic gastrointestinal (GI) and incessant biliary medical disorders, including Barrett's disease, biliary, liver, Crohn's, inflammatory bowel, and peptic ulcer disease, and gastroesophageal reflux disorder (GERD), represent one of the key factors positively influencing the market. In addition, the increasing occurrence of benign pancreas and liver tumors, especially among the geriatric population, along with the growing occurrence of cancer across the globe, is driving the market. In line with this, the expansion of hospitals and diagnostic centers is increasing the need for imaging techniques propelling the market growth.Furthermore, rising investments by governments and healthcare organizations of various countries in advanced endoscopy devices and improve endoscopy research is strengthening the market growth. Apart from this, the shifting consumer preference toward minimally invasive surgeries for a speedy recovery and minimal pain and rising awareness about ERCP devices like sphincterotomes are offering a favorable market outlook. Moreover, continuous improvements in healthcare infrastructure and a considerable rise in medical tourism are expected to propel market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global endoscopic retrograde cholangiopancreatography market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, procedure and end user.Breakup by Product:
- Endoscope
- Endotherapy Devices
- Sphincterotomes
- Lithotripter
- Stents
- Others
- Visualization Systems
- Energy Devices
- Others
Breakup by Procedure:
- Biliary Sphincterotomy
- Biliary Stenting
- Biliary Dilatation
- Pancreatic Sphincterotomy
- Pancreatic Duct Stenting
- Pancreatic Duct Dilatation
Breakup by End User:
- Hospitals and Clinics
- Ambulatory Surgery Centers
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc.Key Questions Answered in This Report
1. How big is the global endoscopic retrograde cholangiopancreatography market?2. What is the expected growth rate of the global endoscopic retrograde cholangiopancreatography market during 2024-2032?
3. What are the key factors driving the global endoscopic retrograde cholangiopancreatography market?
4. What has been the impact of COVID-19 on the global endoscopic retrograde cholangiopancreatography market?
5. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the product?
6. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the procedure?
7. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the end user?
8. What are the key regions in the global endoscopic retrograde cholangiopancreatography market?
9. Who are the key players/companies in the global endoscopic retrograde cholangiopancreatography market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Endoscopic Retrograde Cholangiopancreatography Market
6 Market Breakup by Product
7 Market Breakup by Procedure
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Boston Scientific Corporation
- CONMED Corporation
- Cook Group Incorporated
- Fujifilm Holdings Corporation
- Hobbs Medical Inc.
- Johnson & Johnson
- Medi-Globe GmbH
- Medtronic plc
- Olympus Corporation
- Shaili Endoscopy
- Steris Corporation
- Telemed Systems Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 142 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 1.6 Billion |
| Forecasted Market Value ( USD | $ 2.7 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
